aid: epibiologics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/epibiologics.png
name: EpiBiologics
description: 'EpiBiologics is a clinical-stage biotechnology company based in San Mateo, California,
  developing bispecific antibodies for directed extracellular protein degradation. Its proprietary
  EpiTAC platform leverages an atlas of 270+ degradation-inducing cell-surface receptors to build
  tissue-selective therapies that degrade disease-causing proteins while sparing healthy tissue,
  targeting cancer, autoimmune, and other serious diseases. The company dosed its first patient with
  EPI-326 (an EGFR-driven solid-tumor bispecific) in a Phase 1 study in April 2026 and closed a $107M
  Series B round in January 2026. Backed by GV, EpiBiologics was added to the API Evangelist network as
  a portfolio-lead profile; it publishes a corporate website but no public developer/API surface.'
url: https://raw.githubusercontent.com/api-evangelist/epibiologics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Therapeutics
- Drug Discovery
- Protein Degradation
- Antibodies
- Oncology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.epibiologics.com
- type: About
  url: https://www.epibiologics.com/about-us
- type: Support
  url: https://www.epibiologics.com/contact
- type: DomainSecurity
  url: security/epibiologics-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence